- Reference code :
- wf2576
- Published date :
-
22 July 2004
- Expired date :
-
08 December 2031
“Strong performance from growth products delivers 11 percent increase in sales for the second quarter. Dividend increased by 15 percent.”
Download the narrative
and the figures
.
Media Enquiries:
Steve Brown/Edel McCaffrey (London) (020) 73045033/5034
Staffan Ternby (Södertälje) (8) 553 26107
Rachel Bloom-Baglin (Wilmington) (302) 886 7858
Analyst/Investor Enquiries:
Mina Blair-Robinson (London) (020) 73045084
Jonathan Hunt (London) (020) 7304 5087
Staffan Ternby (Södertälje) (8) 553 26107
Ed Seage/Jörgen Winroth (US) (302) 886 4065/(212) 579 0506
Further enquiries to:
Media Enquiries:
Steve Brown/Edel McCaffrey (London) (020) 73045033/5034
Staffan Ternby (Södertälje) (8) 553 26107
Rachel Bloom-Baglin (Wilmington) (302) 886 7858
Analyst/Investor Enquiries:
Mina Blair-Robinson (London) (020) 73045084
Jonathan Hunt (London) (020) 7304 5087
Staffan Ternby (Södertälje) (8) 553 26107
Ed Seage/Jörgen Winroth (US) (302) 886 4065/(212) 579 0506
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 21-Nov-2009 08:15 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
